Kanabo Group PLC (LSE:KNB) has told its investors that its CBD and nicotine formula has advanced from Patent Cooperation Treaty to phase to National Phase in the US, UK, and EU countries.
The next stage would be to apply for an internationally approved patent for the formula to treat nicotine and tobacco addiction.
Research by the medical cannabis and R&D company, admittedly among “a handful of volunteers” suggests the programme significantly reduces physical and psychological nicotine withdrawal effects by an average of 70%.
Avihu Tamir, chief executive officer of Kanabo said, "Our tests show a dramatic reduction in nicotine consumption, whether in cigarettes or e-cigarettes, which can only be good news for health services around the world."